Register for our free email digests:
Latest From Alpine Biosciences Inc.
Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.
Start-ups raised $1.19 billion in Q3 2014, 33% more than last quarter. Several reverse licensing alliances were penned; five acquisitions were signed, four in biopharma and one in the device sector.
In a transaction worth $650 million in pre-commercial payments, Daiichi Sankyo got exclusive US rights to Charleston Labs’ hydrocodone combos for pain; Roche acquired two of its partners, InterMune and Santaris. Both biopharma and device financing were down in August compared with July.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.
- Antisense, Oligonucleotides
- Large Molecule
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Genta Inc.
- Senior Management
Raymond P Warrell Jr., MD, Chmn. & CEO
Gary Siegel, VP, Fin.
Loretta M Itri, MD, Pres., Pharmaceutical Dev. & CMO
- Contact Info
Phone: (908) 286-9800
200 Connell Dr.
Berkeley Heights, NJ 07922
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.